A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Clinical trial NCT00699842 · TERMINATED

Trial details

NCT number: NCT00699842
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome MDS Low to Intermediate-1 MDS Non-deletion 5q

Start date: 2008-07-01
Primary completion: 2011-01-01
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.